Carrie Cibulskis
Overview
Explore the profile of Carrie Cibulskis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rickles-Young M, Tinoco G, Tsuji J, Pollock S, Haynam M, Lefebvre H, et al.
J Mol Diagn
. 2024 Mar;
26(5):413-422.
PMID: 38490303
Blood-based liquid biopsy is increasingly used in clinical care of patients with cancer, and fraction of tumor-derived DNA in circulation (tumor fraction; TFx) has demonstrated clinical validity across multiple cancer...
2.
Sato T, Montazeri K, Gragoudas E, Lane A, Aronow M, Cohen J, et al.
JCO Precis Oncol
. 2024 Jan;
8:e2300368.
PMID: 38237100
Purpose: Somatic chromosomal alterations, particularly monosomy 3 and 8q gains, have been associated with metastatic risk in uveal melanoma (UM). Whole genome-scale evaluation of detectable alterations in cell-free DNA (cfDNA)...
3.
Abbou S, Klega K, Tsuji J, Tanhaemami M, Hall D, Barkauskas D, et al.
J Clin Oncol
. 2023 Feb;
41(13):2382-2393.
PMID: 36724417
Purpose: Novel biomarkers are needed to differentiate outcomes in intermediate-risk rhabdomyosarcoma (IR RMS). We sought to evaluate strategies for identifying circulating tumor DNA (ctDNA) in IR RMS and to determine...
4.
Penter L, Liu Y, Wolff J, Yang L, Taing L, Jhaveri A, et al.
Blood
. 2023 Jan;
141(15):1817-1830.
PMID: 36706355
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026...
5.
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5066-5078.
PMID: 36215125
Purpose: Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from the combination of palbociclib plus ET in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. Bazedoxifene is a third-generation...
6.
Gibson C, Kim H, Zhao L, Murdock H, Hambley B, Ogata A, et al.
J Clin Oncol
. 2021 Nov;
40(2):189-201.
PMID: 34793200
Purpose: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on...
7.
Weber Z, Collier K, Tallman D, Forman J, Shukla S, Asad S, et al.
Genome Med
. 2021 May;
13(1):89.
PMID: 34016182
Background: Circulating tumor DNA (ctDNA) offers minimally invasive means to repeatedly interrogate tumor genomes, providing opportunities to monitor clonal dynamics induced by metastasis and therapeutic selective pressures. In metastatic cancers,...
8.
Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash E, et al.
Blood
. 2021 Mar;
137(23):3212-3217.
PMID: 33720354
Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune checkpoint blockade in this clinical setting with ipilimumab or nivolumab....
9.
Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, et al.
Clin Cancer Res
. 2020 Dec;
27(18):5049-5061.
PMID: 33323402
Purpose: Whole-exome (WES) and RNA sequencing (RNA-seq) are key components of cancer immunogenomic analyses. To evaluate the consistency of tumor WES and RNA-seq profiling platforms across different centers, the Cancer...
10.
Han G, Hwang J, Wankowicz S, Zhang Z, Liu D, Cibulskis C, et al.
JCO Precis Oncol
. 2020 Sep;
1.
PMID: 32913968
Purpose: Patients with castration-resistant prostate cancer (CRPC) receive second-generation androgen-deprivation therapy, but frequently experience relapse or do not respond. Understanding the genetic mechanisms of resistance will help to identify strategies...